COVID 19 pneumonia in Down syndrome patients : About 2 cases
© 2021 Published by Elsevier Ltd on behalf of IJS Publishing Group Ltd..
INTRODUCTION: Covid-19 is a severe emerging infection with high rate of mortality. Patients with Covid-19 and Down syndrome represent a high rate of morbidity and mortality.
CASE PRESENTATION: Case 1: A 27-year-old white male with Down's syndrome admitted to the ICU for Covid-19 infection with lung damage of 30-50%. The patient improved and referred to the pulmonology department.Case 2: A 49-year-old man admitted to the ICU for Covid-19 infection with a lung damage of 50%. The evolution was lethal and he passed away after 12 days of his admission.
CONCLUSION: People suffering from Down syndrome should be given priority in the management of acute respiratory distress following infection with SARS COV2, or even candidates for early immunosuppressive treatment and possible vaccination once started.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:65 |
|---|---|
| Enthalten in: |
Annals of medicine and surgery (2012) - 65(2021) vom: 25. Mai, Seite 102324 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
El Kaouini, Abderrahim [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 pneumonia |
|---|
| Anmerkungen: |
Date Revised 02.04.2024 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1016/j.amsu.2021.102324 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM324610122 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM324610122 | ||
| 003 | DE-627 | ||
| 005 | 20240402232713.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.amsu.2021.102324 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1360.xml |
| 035 | |a (DE-627)NLM324610122 | ||
| 035 | |a (NLM)33907623 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a El Kaouini, Abderrahim |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a COVID 19 pneumonia in Down syndrome patients |b About 2 cases |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 02.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2021 Published by Elsevier Ltd on behalf of IJS Publishing Group Ltd. | ||
| 520 | |a INTRODUCTION: Covid-19 is a severe emerging infection with high rate of mortality. Patients with Covid-19 and Down syndrome represent a high rate of morbidity and mortality | ||
| 520 | |a CASE PRESENTATION: Case 1: A 27-year-old white male with Down's syndrome admitted to the ICU for Covid-19 infection with lung damage of 30-50%. The patient improved and referred to the pulmonology department.Case 2: A 49-year-old man admitted to the ICU for Covid-19 infection with a lung damage of 50%. The evolution was lethal and he passed away after 12 days of his admission | ||
| 520 | |a CONCLUSION: People suffering from Down syndrome should be given priority in the management of acute respiratory distress following infection with SARS COV2, or even candidates for early immunosuppressive treatment and possible vaccination once started | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a COVID-19 pneumonia | |
| 650 | 4 | |a Cytokinic storm | |
| 650 | 4 | |a Down syndrome | |
| 650 | 4 | |a Immune deregulation | |
| 650 | 4 | |a Pro-inflammatory factors | |
| 700 | 1 | |a El Rhalete, Abdelilah |e verfasserin |4 aut | |
| 700 | 1 | |a Aabdi, Mohammed |e verfasserin |4 aut | |
| 700 | 1 | |a Azizi, Mohammed |e verfasserin |4 aut | |
| 700 | 1 | |a Maarad, Mohammed |e verfasserin |4 aut | |
| 700 | 1 | |a Bahouh, Choukri |e verfasserin |4 aut | |
| 700 | 1 | |a Bkiyer, Houssam |e verfasserin |4 aut | |
| 700 | 1 | |a Housni, Brahim |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of medicine and surgery (2012) |d 2012 |g 65(2021) vom: 25. Mai, Seite 102324 |w (DE-627)NLM245154396 |x 2049-0801 |7 nnns |
| 773 | 1 | 8 | |g volume:65 |g year:2021 |g day:25 |g month:05 |g pages:102324 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.amsu.2021.102324 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 65 |j 2021 |b 25 |c 05 |h 102324 | ||